

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions of claims in the subject application.

1. (currently amended) A combination for the treatment of neuropathic pain comprising an alpha-2-delta ligand selected from (3S,4S)-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid; (3S,5R)-3-Amino-5-methyl-octanoic acid; and pharmaceutically acceptable salts thereof and an atypical antipsychotic, ~~or~~ selected from ziprasidone and pharmaceutically acceptable salts thereof.
2. (cancelled)
3. (cancelled)
4. (cancelled)
5. (cancelled)
6. (cancelled)
7. (currently amended) A pharmaceutical composition for the curative, prophylactic or palliative treatment of neuropathic pain comprising a therapeutically effective amount of a combination according to ~~any one of claims 1-6, or pharmaceutically acceptable salts thereof~~ Claim 1 and a suitable carrier or excipient.
8. (cancelled)
9. (cancelled)
10. (cancelled)

11. (cancelled)
12. (currently amended) A product containing and alpha-2-delta ligand selected from (3S,4S)-(1-Aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid; (3S,5R)-3-Amino-5-methyl-octanoic acid; and pharmaceutically acceptable salts thereof and an atypical antipsychotic, ~~or~~ selected from ziprasidone and pharmaceutically acceptable salts thereof, as a combined preparation for simultaneous, separate or sequential use in the treatment of neuropathic pain.